Drug Type Drug conjugates |
Synonyms |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bladder Cancer | Preclinical | US | 01 Jul 2024 | |
Colorectal Cancer | Preclinical | US | 01 Jul 2024 | |
Head and Neck Neoplasms | Preclinical | US | 01 Jul 2024 | |
Kidney Neoplasms | Preclinical | US | 01 Jul 2024 | |
Lung Cancer | Preclinical | US | 01 Jul 2024 | |
Pancreatic Cancer | Preclinical | US | 01 Jul 2024 | |
Skin Neoplasms | Preclinical | US | 01 Jul 2024 |